Patients without RAS or RAF mutations profit from anti‐EGFR antibody therapy (Karapetis et al, 2008; Van Cutsem et al, 2009), while patients with BRAF‐mutant CRC now receive first‐line therapy combinations of anti‐EGFR antibodies and BRAF kinase inhibitors (Corcoran et al, 2018). The gene discussed is EGFR; the disease is colorectal carcinoma.